BRCA2 pathogenic variants increase the risk of prostate cancer development by 3- to 8.5-fold and are associated with aggressiveness and high mortality,1 prompting early screening for BRCA2 carriers.2 This evidence concerns the gene BRCA2 and prostate carcinoma.